Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., Glen, R., Grigorov, M., Hammond-Kosack, K., Harland, L., Hopkins, A., Larminie, C., Lynch, N., Mann, R. K., Murray-Rust, P., Lo Piparo, E., Southan, C., Steinbeck, C., Wishart, D., Hermjakob, H., Overington, J., Thornton, J. (2011) Minimum information about a bioactive entity (MIABE). NATURE REVIEWS DRUG DISCOVERY, 10 (9). pp. 661-669. ISSN 1474-1776

Full text not available from this repository.

Abstract

Bioactive molecules such as drugs, pesticides and food additives are produced in large numbers by many commercial and academic groups around the world. Enormous quantities of data are generated on the biological properties and quality of these molecules. Access to such data - both on licensed and commercially available compounds, and also on those that fail during development - is crucial for understanding how improved molecules could be developed. For example, computational analysis of aggregated data on molecules that are investigated in drug discovery programmes has led to a greater understanding of the properties of successful drugs. However, the information required to perform these analyses is rarely published, and when it is made available it is often missing crucial data or is in a format that is inappropriate for efficient data-mining. Here, we propose a solution: the definition of reporting guidelines for bioactive entities - the Minimum Information About a Bioactive Entity (MIABE) - which has been developed by representatives of pharmaceutical companies, data resource providers and academic groups.

Item Type:	Review Article
Authors (ICR Faculty only):	Al-Lazikani, Bissan
All Authors:	Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., Glen, R., Grigorov, M., Hammond-Kosack, K., Harland, L., Hopkins, A., Larminie, C., Lynch, N., Mann, R. K., Murray-Rust, P., Lo Piparo, E., Southan, C., Steinbeck, C., Wishart, D., Hermjakob, H., Overington, J., Thornton, J.
Additional Information:	ISI Document Delivery No.: 814TC Times Cited: 0 Cited Reference Count: 27 Orchard, Sandra Al-Lazikani, Bissan Bryant, Steve Clark, Dominic Calder, Elizabeth Dix, Ian Engkvist, Ola Forster, Mark Gaulton, Anna Gilson, Michael Glen, Robert Grigorov, Martin Hammond-Kosack, Kim Harland, Lee Hopkins, Andrew Larminie, Christopher Lynch, Nick Mann, Romeena K. Murray-Rust, Peter Lo Piparo, Elena Southan, Christopher Steinbeck, Christoph Wishart, David Hermjakob, Henning Overington, John Thornton, Janet European Commission under the Proteomics Standards Initiative and International Molecular Exchange (PSIMEx)[FP7-HEALTH-2007-223411] This work has, in part, been funded by the European Commission under the Proteomics Standards Initiative and International Molecular Exchange (PSIMEx), contract number FP7-HEALTH-2007-223411. Nature publishing group London
Uncontrolled Keywords:	binding-sites druggability ontology database genome
Research teams:	ICR divisions > Cancer Therapeutics > Computational Biology
Depositing User:	Barry Jenkins
Date Deposited:	19 Sep 2011 14:54
Last Modified:	19 Sep 2011 14:54
URI:	http://publications.icr.ac.uk/id/eprint/11030

Actions (login required)

View Item